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Descriptor: 
At a glance commentary 
Scientific Knowledge. The elderly suffer a high incidence of and impact from pneumonia, 
especially when sepsis develops.  Impaired neutrophil responses during severe infections and 
sepsis have been associated with poor outcomes. Little is known about neutrophil functions during 
mild to moderate infection events.   Therapeutic interventions with statins aimed at improving 
poor clinical outcomes and immune responses have focused on critically ill patients, without 
success.  
What this adds 
Inaccurate neutrophil migration seen in aging deteriorates further with infection severity. Sepsis 
was associated with a severe impairment of migration that did not recover weeks after the initial 
event. When used at high dose, in elderly subjects in health or in vitro in milder infective events, 
simvastatin improved neutrophil migratory accuracy without impeding other vital bactericidal 
functions, suggesting a therapeutic role if used early as adjuvant therapy.  Simvastatin could not 
restore neutrophil functions in vitro in more severe sepsis episodes, corroborating interventional 
trial results. 
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Abstract (250 words) 
Rationale:  Dysregulated neutrophil functions are described with age and sepsis. Statins are 
associated with improved infection survival in some observational studies but trials in critically ill 
patients have not shown benefit.  Statins also alter neutrophil responses in vitro. 
Objective: To assess neutrophil migratory accuracy with age during respiratory infections and 
determine if and how a statin intervention could alter these blunted responses. 
Methods. Migratory accuracy of blood neutrophils from young (aged<35) and old (aged>60) 
patients in health, during a lower respiratory tract infection (LRTI), pneumonia (CAP) and 
pneumonia associated sepsis (S-CAP) was assessed with and without simvastatin. In vitro results 
were confirmed in a double-blinded randomised clinical trial in healthy elders. Cell adhesion 
markers were assessed. 
Results: In vitro neutrophil migratory accuracy in the elderly deteriorated as the severity of the 
infectious pulmonary insult increased, without recovery at six weeks. Simvastatin rescued 
neutrophil migration with age and during mild-moderate infection, at high dose in older adults, but 
not during more severe sepsis. Confirming in vitro results, high dose (80mg) simvastatin improved 
neutrophil migratory accuracy without impeding other neutrophil functions in a randomised, 
double-blinded clinical trial in healthy elders. Simvastatin modified surface adhesion molecule 
expression and activity, facilitating accurate migration in the elderly.  
Conclusions: Infections in older adults are associated with prolonged, impaired neutrophil 
migration, potentially contributing to poor outcomes. Statins improve neutrophil migration in vivo 
in health and in vitro in milder infective events but not in severe sepsis, supporting their potential 
utility as an early intervention during pulmonary infections. 
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Introduction 
Pneumonia is the leading infectious cause of death in developed countries. Deaths are highest in 
the elderly with mortality rates not improved over the last decade(1). Neutrophils are key effector 
cells during bacterial infections, with evidence of sub-optimal immune responses in the elderly 
contributing to poor outcomes(2).   In vitro, age is associated with reduced neutrophil migratory 
accuracy(3), phagocytosis(4) and NETosis(5), although degranulation appears increased(3).  Poor 
migratory accuracy, reduced bactericidal function and enhanced degranulation may delay 
pathogen clearance and increase by-stander tissue damage through excess protease activity.  
Consistent with this, older adults experience greater  end-organ damage following severe 
infections(6).   
 
Sepsis related  organ dysfunction is  caused by complex, dysregulated host responses to  infection 
and is more common in the elderly(7). Patients with severe sepsis demonstrate a sustained pro-
inflammatory cytokine profile(8), abrogated anti-inflammatory signalling(9) and dysregulated 
neutrophil functions(8). This results in a hostile yet immunoparesed systemic environment.   
Secondary infections are common following sepsis, and are associated with immune 
suppression(10).  
 
Given the increasing incidence of sepsis, there is interest in enhancing immune responses to clear 
infections before sepsis develops.  To date, there are no treatments that improve immune cell 
function during established sepsis(11).  Although variable, most infections begin with a milder 
syndrome that progresses to sepsis in vulnerable individuals. It is unknown if milder infections are 
associated with immune dysfunction which deteriorates as the severity of insult increases or at 
what point during the infective process immune cells are susceptible to therapeutic interventions. 
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HMG CoA Reductase inhibitors (statins) lower cholesterol but some population studies and 
clinical trials have suggested survival benefits during infection(12). Pre-dosing with statins 
improves outcomes in sepsis murine models(13).   However, preclinical studies have not translated 
to positive outcomes in a recent trial of patients with severe sepsis related acute respiratory 
distress syndrome (ARDS) (14). 
 
In vitro, statins alter neutrophil functions including migration and NETosis(15, 16) with mechanisms 
including reduced adhesion molecule expression(17).  Neutrophil adhesion molecule expression 
increases with sepsis(18, 19) but it is unclear whether statins alter neutrophil adhesion molecule 
expression during infections, and whether this might improve or hinder cellular responses to 
infection. There are many unanswered questions about the non-cholesterol lowering effects of 
statins and there is considerable interest in how statins might improve inflammatory outcomes. 
Currently 209 clinical trials are registered with Clinical Trials Gov. to study these effects (20).   
 
We hypothesised that poorer outcomes during infections in the elderly reflected a progressive 
exaggeration of the age-related decline in neutrophil functions.  Furthermore, we proposed that 
statins would restore aspects of neutrophil function during these events, but that there would be a 
window of opportunity for therapeutic response. 
   
The aims of the present study were: 1. To assess whether age-associated reductions in neutrophil 
migratory accuracy(3) were exaggerated during episodes of lower respiratory tract infection 
(LRTI), community acquired pneumonia (CAP) and pneumonia associated sepsis (S-CAP); 2. To 
determine if in vitro treatment with simvastatin improved neutrophil migration in health, LRTI, 
CAP and S-CAP, and at which concentration; 3. To assess the effects of oral simvastatin on 
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systemic neutrophil functions in healthy older subjects in a proof of concept randomised 
controlled trial 4. To determine the likely mechanisms of effect. 
Some of the results of these studies have been reported previously in the form of an abstract(21). 
Materials and Methods 
Study subjects 
All patients were aged >60 years or <35 years and recruited between 2011-2016.  Healthy Old 
(OH) and young (YH) subjects, identified from the Birmingham 1000 Elders cohort(3), had never 
smoked, had no evidence of acute or chronic disease, normal spirometry, were medication free and 
had no previous episodes of hospitalised sepsis. Older subjects on statins (OS) were taking 40mg 
Simvastatin due to cardiovascular risk (with no previous cardiovascular events).    
Patients with a LRTI, CAP and S-CAP were recruited within 24 hours of admission to hospital. 
LRTI was diagnosed by the presence of increased breathlessness, a cough productive of purulent 
sputum without associated consolidation on chest radiograph and without sepsis(22). CAP was 
diagnosed using standard criteria(23) including symptoms of a respiratory infection and new chest 
radiograph consolidative changes and patients had CURB scores of 1–2 (excluding the point given 
for age), indicating mild to moderate severity(24) and without sepsis.   Patients with S-CAP met 
criteria for pneumonia(23) and sepsis(22). This research utilized the 2012 definition of sepsis to 
allow comparison with published literature(22). The newer 2015 definition identifies a population at 
high-risk of in-hospital mortality but excludes milder infections, which this study sought to 
investigate(25). All diagnoses were confirmed by a senior Pulmonologist. All subjects with capacity 
gave informed written consent and those without were recruited using a personal consultee 
following approval from the South/Central Oxford Research Ethics Committee (Reference 
11/SC/0356).   
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Detailed materials and methods are given in the online supplement including sputum sol 
preparation which was prepared as previously described(26). 
 
Isolation of blood neutrophils 
Neutrophils were isolated from whole blood as described(3) and were >95% pure, >97% viable, by 
exclusion of trypan blue.  
 
Neutrophil Migration 
Migration was assessed using an Insall Chamber (Weber Scientific International Ltd, Teddington, 
UK) as described(3), full methods are provided in the online supplement. Neutrophils were adhered 
to coverslips coated with 7.5% culture-tested bovine serum albumin (Sigma-Aldrich, UK) 
(suspended at 2x106/ml). The chamber was filled with RPMI 1640 (control), 100 nM Interleukin-8 
(CXCL8) (R&D Systems, Abingdon, UK) or 100nM Formyl-Methionyl-Leucyl-Phenylalanine 
(fMLP;Sigma-Aldrich). Cells were incubated with simvastatin hydroxy acid (Sigma Aldrich) at 
500 pM - 1 µM. This range was chosen as it includes concentrations which have been described in 
patients taking simvastatin orally(27)), 26 nM BIRT-377 (a CD11a inhibitor(28); Tocris, Abingdon, 
UK) or relevant vehicle control for 40 minutes prior to migration.   
 
Video-microscopy for migratory dynamics 
Time-lapse recordings used a Leica DMI6000B inverted microscope fitted with a DFC360FX 
camera.  Recordings lasted 12 minutes, with slides captured using Leica LAS-AF software. 
ImageJ (Wayne Rasband, NIH, MD, USA) was used to analyse cell tracks. All analysis was 
carried out by a single analyst, blinded to subject group and cell condition.      
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Neutrophil migratory accuracy (termed “chemotaxis” and measured in μm/minute) was defined as 
distance travelled over time only in the direction of the stable chemotactic gradient formed using 
the Insall chamber(29). This is different than migratory speed, which is movement in any direction 
over time (termed “chemokinesis”).  
 
Neutrophil Phagocytosis and NET generation 
Neutrophil phagocytosis was assessed using the commercial pHrodo assay (Invitrogen Life 
Technologies, California, USA) as per manufacturer’s instructions.  Data were expressed as 
phagocytic index: Phagocytic Index = % of phagocytosing neutrophils X mean fluorescence 
intensity (MFI). Neutrophil extracellular trap (NET) production was measured as described(5) in 
quiescent or stimulated neutrophils (with fMLP 100nM; LPS 100nM) and PMA 25nM (used here 
as a positive control), cell free DNA was labelled and the degree of fluorescence measured. NET 
release was confirmed by light microscopy.  
 
Placebo-controlled double-blind cross-over trial of Simvastatin in the healthy elderly 
A randomized placebo-controlled, double-blind cross over trial (RCT) recruited healthy elderly 
subjects to receive oral Simvastatin 80mg or placebo once daily for 2 weeks, followed by a two 
week-wash out period and then the alternative, blinded therapy. Computer-based block 
randomisation was performed in a 1:1 ratio by a centralised service (Bilcare Ltd, UK).  
Participants had blood samples taken pre-randomisation and following the first and second two 
weeks’ intervention. The primary outcome was an improvement from baseline in neutrophil 
chemotaxis.  Secondary endpoints were changes in other neutrophils functions, safety and 
tolerability. The trial protocol is summarized in the online supplement where inclusion and 
exclusion criteria are given in Table S1. Throughout, both participants and researchers were 
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blinded to treatment and researchers remained blinded to treatment until all study assays were 
complete (including cholesterol levels). 
 
Neutrophil Adherence  
Neutrophil adherence (%) was the number of adherent cells present within the field of view 
divided by the total number of cells in the field multiplied by 100.  Adherence was defined by 
plotting visual appearance using Image J (Wayne Rasband, NIH, MD, USA); those with a 
polarized morphology with a clear leading edge and uropod at the rear of the cell were considered 
adherent, compared to spherical cells without a polarized morphology, which were classified as 
non-adherent cells.  This was assessed by two independent viewers blinded to the experimental 
condition and the median result reported. 
 
Adhesion markers 
100 µl whole blood collected in lithium heparin vacutainers was washed and re-suspended in 2% 
PBS/BSA containing 5% autologous plasma. Whole blood was incubated ±1µM simvastatin or 
vehicle control for 40 minutes at 37OC prior to staining. Marker expression was determined by 
flow cytometry (Accuri C6, BD Biosciences, USA) counting 10,000 events. Data are presented as 
Median Fluorescence Index (MFI) minus signal from irrelevant antibody or percentage change in 
MFI, as stated in the text. Antibodies are given in the online supplement.  
 
Statistics 
Statistical analyses were carried out using PASW v18.0 (Chicago, IL, USA).   Data were tested for 
normality using Kolmogorov-Smirnov but differences between groups were assessed using non–
parametric tests due to sample size including Wilcoxon signed rank, Mann-Whitney, Kruskal 
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Wallis or Friedman’s tests. Differences between categorical variables were assessed using χ2 test 
and correlations using Spearman’s correlation coefficient.  
 
RCT. There were no previous studies of the impact of oral simvastatin on neutrophil functions 
from which to determine accurate power calculations.  Our in vitro studies reported mean 
differences of effect of between 1.8μm/min, SD 0.6μm/min (OH neutrophils incubated with 
simvastatin 1µM or vehicle control) to 0.67um/min, SD 0.52 (comparing adults taking 40mg 
Simvastatin to those not on Simvastatin therapy) and using these data we predicted that 
approximately 18 participants completing each arm would detect a significant improvement in 
neutrophil chemotaxis with a power of 80%. To allow for dropouts, a target recruitment of 24 
participants was selected. Differences between pre and post treatment values for each group were 
used for data analysis. Holm-bonferroni correction was applied for multiple comparisons. 
 
All statistical tests were 2 sided with p<0.05 accepted as statistically significant.  Figure legends 
provide information on which statistical tests were employed. 
 
Results 
Participant demographics and baseline sepsis severity scores are shown in Table 1.  
 
Neutrophil migratory accuracy declines with increasing infectious insult in older subjects   
Neutrophils from OH were less able to migrate accurately to CXCL8 than those isolated from YH 
(Mean chemotaxis (+SEM): OH 1.3µm/min + 0.1; YH 1.8µm/min + 0.2, p<0.001, Mann Whitney 
test, n=10 each group).  
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Cross-sectionally, there was a progressive decrease in the ability of systemic neutrophils from old 
subjects to accurately migrate (chemotaxis) towards CXCL8 as the severity of their infection 
worsened from LRTI to CAP to S-CAP (Kruskall Wallis, p<0.0001). In contrast neutrophils from 
young subjects displayed a different response; with no deterioration in neutrophil migratory 
accuracy across patient groups (Kruskal Wallis; non-significant) but a reduction of accuracy 
during S-CAP compared with health (Mann Whitney, p=0.01).  See Figure 1A. There were no 
differences in treatments for the acute infection between young or old LRTI, or young or old CAP 
or young or old S-CAP patients to account for these differences. 
 
Responses to single chemokines may not reflect responses to complex biological secretions and so 
neutrophils from older and younger pneumonia patients (n=5 per group) migrated towards pooled 
“pneumonia” sputum from old patients. Neutrophils from old CAP patients displayed a reduced 
ability to migrate towards this complex, inflammatory, biological stimulus compared to 
neutrophils from young CAP patients (Chemotaxis: Old 0.6µm/minute + 0.2 Vs. Young 
2.2µm/minute + 0.2, p=0.008, Mann Whitney test), replicating the single chemokine results.  
 
Migratory studies were repeated in the CAP subjects (n=10 for both young and old CAP groups) 
six weeks after admission, after a physician confirmed resolution of chest radiograph changes and 
no symptoms or signs of infection.  CAP and recovery results (CAP-R) were compared with age-
matched controls who self-reported having never had a pneumonia (HC, n=10 for each group).  
Neutrophils from younger subjects did not alter in their migratory accuracy during or following 
infection, or when compared to other young healthy controls (Median (range) chemotaxis 
(µm/min) CAP 2.64 (1.24-3.21), CAP-R 1.88 (1.26- 2.54); YH 1.81 (1.09- 2.66)).  Neutrophils 
from old CAP patients did not improve their migratory accuracy at six weeks post infection and 
neutrophil migratory accuracy did not reach average levels seen in OH adults (Median (range) 
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chemotaxis (µm/min) CAP 0.51 (-0.16 – 1.03); CAP-R 0.72 (0.16 -1.57), HC 1.22 (0.93 – 1.92); 
Mann Whitney CAP-R compared to OH, p=0.002). See Figure 1B.  
 
In vitro Simvastatin exposure and neutrophil migratory dynamics 
A dose response was conducted with Simvastatin (500pM–1µM) incubated with neutrophils 
isolated from OH (n=10). Simvastatin improved neutrophil migratory accuracy, with 1µM 
simvastatin being optimal (Figure 2). When old and young healthy participants were compared, 
1µM simvastatin increased chemotaxis in OH but not neutrophils from YH (OH vehicle control 
0.43μm/min+0.1, simvastatin 2.2μm/min+0.1, p=0.001, YH vehicle control, 1.4μm/min+0.2, 
simvastatin 1.8μm/min+0.2, p=ns, Wilcoxon signed rank tests).  
 
Neutrophils from old patients taking simvastatin 40mg daily have an augmented migration 
response when exposed to high dose simvastatin in vitro 
Previous experiments assessed simvastatin following a single in vitro exposure but clinical studies 
support the benefits of a priori use(30). Isolated neutrophil migration was assessed in OS (n=10) 
taking 40mg simvastatin daily with self-reported compliance. Demographics are in Table 1.  
Simvastatin use was associated with increased neutrophil migratory accuracy compared to age-
matched adults not taking statins, (Chemotaxis: OH 0.43μm/min+0.1; OS 1.1μm/min+0.2, 
p=0.008). Incubation of statin-user’s neutrophils with 1µM simvastatin improved migratory 
accuracy towards CXCL8 (Chemotaxis; vehicle control 1.1μm/min+0.2, Simvastatin treatment 1.8 
μm/min+0.3, p=0.02), suggesting high dose therapy may have immune effects even in prior statin 
users (Mann Whitney tests for all comparisons). 
 
 11 
Statins improve neutrophil migration during respiratory infections but not sepsis in older 
patients 
Neutrophils from patients with a LRTI, CAP and S-CAP (described in Table 1) were incubated 
with simvastatin (1µM) or vehicle control. Simvastatin improved neutrophil migration from old 
patients with LRTI and CAP but had no effect on neutrophils from patients with S-CAP (Figure 
3A).  Simvastatin did not improve neutrophil migratory accuracy in young patients with a LRTI, 
CAP or S-CAP (Figure 3B).   
 
These cross-sectional, in vitro results suggest neutrophil migratory accuracy declines with the 
severity of an infective insult in older adults, and does not reach levels seen in healthy old adults 
after clinical recovery. Simvastatin can restore neutrophil migratory accuracy in vitro, in health 
and during mild to moderate respiratory infections, but not during a severe septic event and only at 
high dose in cells from older adults. 
 
Simvastatin improves neutrophil migratory accuracy in the healthy elderly without 
inhibiting other cell functions – Randomised Control Trial outcomes.  
To assess if these in vitro results could be reproduced in vivo, a proof of concept, randomised 
double-blinded placebo controlled cross-over trial was performed with healthy older adults given 
80mg simvastatin or placebo orally. The modified consort diagram for the trial is given in Figure 
4.  Participant demographics are shown in Table 2.   
 
Trial Outcomes 
Mean age was 71.9 years (range 60-94) with a similar sex distribution (Male, 9 vs.12 p=0.661; χ2 
test). Treatment compliance was excellent with only one subject forgetting a single dose. Total 
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cholesterol (measured as a surrogate for compliance) was studied post trial completion. Placebo 
had no impact on serum cholesterol levels whilst simvastatin treatment significantly reduced 
cholesterol levels and was well tolerated (see online supplement). 
 
Neutrophil chemotaxis was significantly improved from baseline in subjects following simvastatin 
treatment when neutrophils migrated towards fMLP (median change in migratory accuracy, 
0.34μm/min (IQR 0.05 - 0.72) vs. -0.05μm/min (IQR -0.38 - 0.08μm/min), p=0.006. A trend 
towards improvement in neutrophil migratory accuracy was seen when migrating towards CXCL-
8, but this was not significant following corrections for multiple comparisons (median change 
0.26μm/min (IQR 0.01- 0.61) vs. 0.03μm/min (IQR -0.73- 0.34) p=0.042). Simvastatin treatment 
did not affect neutrophil phagocytosis or NETosis (see Figure 5 and Table 3, all Wilcoxon-signed 
rank tests). 
 
Mechanism of action – the effect on adhesion and adhesion markers 
Neutrophils from old subjects in health, LRTI, CAP and S-CAP (n=10 per group) displayed 
increased cover-slip adherence as the infectious insult increased (median percent adherent (IQR) 
OH: 51% (39-64), LRTI 61% (38-87), CAP 68% (55-98), S-CAP 91% (82-100), Kruskall Wallis, 
p=0.008)).  Although a similar pattern was seen in young patients, this was not significant (median 
percent adherent (IQR); YH: n=10, 35% (28-41), LRTI, n=8, 40% (29-53), CAP, n=10, 42% (29-
62), S-CAP, n=10, 86% (53-100), p=0.1).  
 
To determine if increased adhesion reflected changes in surface expression of adhesion markers, 
CD11a, CD11b, CD18 and activated CD11b were measured on quiescent neutrophils in whole 
blood.   CD11b and CD11a expression was higher on neutrophils from OH compared with YH 
(n=10 each group).   Surface expression of CD11b and CD11a were then measured on neutrophils 
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in whole blood from old CAP patients and compared to OH (n=10 each group) with higher 
expression of CD11a.   Incubating OH whole blood with 1uM simvastatin in vitro (or vehicle 
control (VC)) was associated with a reduction in CD11a expression on neutrophils compared with 
vehicle control.  See table 4. 
 
To determine if CD11a expression was associated with migratory accuracy, relationships between 
expression and migratory accuracy (chemotaxis) were explored.  There was a negative correlation 
between CD11a expression and neutrophil migratory accuracy (Spearman’s correlation -0.69, 
p=0.03) in cells from OH which was not seen when CD11a expression was compared to the 
migratory accuracy of neutrophils from YH (Spearman’s correlation 0.28, p=0.43), n=10 each 
group.    The negative correlation between CD11a expression and neutrophil migratory accuracy 
was no longer present when OH whole blood was treated with Simvastatin in vitro (Spearman’s 
correlation -0.26, p=0.47). 
  
To further assess this relationship, neutrophils from YH or OH (n=10 each group) were incubated 
with the LFA-1 antagonist BIRT-377 or vehicle control and migrated towards CXCL8 (100nM).   
Compared to vehicle control, neutrophils from young adults demonstrated a median reduction in 
chemotaxis of -47.3% (-4.6 - -71.1), p=0.006 while neutrophils from old adults displayed an 
increase in chemotaxis (percentage increased 29.8% (5.4 -49.0), p=0.03).   See Figure 6.  
 
Discussion 
We present a substantial and novel body of work demonstrating that neutrophils isolated from old 
adults with an increasing severity of acute pulmonary infections display a progressive impairment 
of migratory accuracy. Young adults displayed a different response, with neutrophil migratory 
accuracy only impaired during severe septic events. Neutrophil migration is associated with 
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proteases and reactive oxygen species release(31) and meandering migratory pathways may 
increase tissue exposure to these injurious proteins(3), potentially increasing inflammatory burden 
and tissue damage, possibly contributing to end organ damage.  Furthermore, following clinical 
recovery, neutrophils from older adults did not achieve the migratory accuracy present in healthy 
age-matched peers. These are cross-sectional data, and while it is possible that neutrophil 
migratory accuracy declines as the infectious insult progresses within an individual, it is also 
possible that these patients had poorer neutrophil migratory accuracy prior to their infection.  Only 
prospective studies would be able to differentiate between these two possibilities, however, either 
may have clinical significance as clinical data suggest older pneumonia patients experience 
secondary infections that account for 30% of readmissions(32), and those with a poor immune 
response on admission have a worse long-term prognosis(33). 
 
In vitro migratory accuracy in neutrophils from old donors was enhanced by simvastatin but only 
at higher concentrations. Neutrophil migration could be rescued in vitro by simvastatin during a 
LRTI and CAP, but not during a severe septic event and not in young donors.  This might support 
the use of high dose simvastatin pre-emptively or early during an infective insult in the elderly but 
suggests a lack of efficacy would be seen in established severe sepsis, corroborating data from 
interventional trials(12). In vitro chemotaxis findings were replicated for fMLP in the interventional 
trial in healthy older adults without impeding other vital neutrophil functions, such as 
phagocytosis and NET release.   Neutrophil migratory accuracy towards CXCL8 was also 
increased in the clinical trial, but this did not reach significance when the p value was corrected 
for multiple comparisons.     
 
The current study also suggests a mechanism of the effect, that of increasing adhesion marker 
expression with age and infection, which simvastatin reduced. There was a negative correlation 
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between CD11a expression and neutrophil migratory accuracy to CXCL8 in old adults and BIRT-
377 was able to improve neutrophil chemotaxis from old but not young donors. There is a wealth 
of data suggesting that adhesion markers are increased in sepsis(34, 35)  and that statins can reduce 
their expression and function(36). However, the current study is the first to link the increase in 
adhesion markers on neutrophils with poor migratory accuracy, show that statins can reduce 
expression of adhesion markers during an infection, and that inhibiting adhesion marker activity 
(here via a selective inhibitor) replicates the improvement in neutrophil chemotaxis seen following 
statin exposure, mechanistically linking these findings.  
 
Certain statins can alter adhesion molecule LFA-1 (containing CD11a) binding to ICAM-1(37) but 
direct  steric hindrance is not the only potential mechanism, as statins have been shown to reduce 
surface expression of CD11a via small GTPase dependent mechanisms with mevalonate reversing 
these effects(38-40).  Small GTPase activity can also be modified by PI3K signaling, a pathway 
already implicated in aberrant migration in the elderly(3).  Furthermore, CDC42 activity, a small 
GTPase implicated in cell polarization and neutrophil migratory accuracy(41) through adhesion 
marker activity(42), has been recently shown to be increased with age and with diseases associated 
with aging(43).  
 
There is great interest in re-purposing medications in novel settings. The disparity in outcomes of 
statin studies may reflect there being a therapeutic window of benefit for patients – with this 
window influenced by statin dose, participant age and infection severity. One study found benefit 
in high dose statin intervention in patients with moderate severity sepsis if given early during 
presentation(44) but recent interventional studies have found no survival benefit in a severe sepsis 
group including patients with ARDS(13). A meta-analysis statin clinical trials in patients without 
infection found no improvement in subsequent infection rates following a year of statin or placebo 
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use. However, studies included a wide range of patients and diseases, infection was not the 
primary outcome and many utilised “low” statin doses(45). A more recent meta-analysis of patients 
admitted with infections suggested survival benefit with statins, but only in less severe cases(46). 
Simvastatin could attenuate lung damage following inhalation injury in mice, but only at high 
dose(47). In a double-blind placebo-controlled study the endotoxin-induced systemic inflammatory 
response was reduced by pre-emptive 80mg Simvastatin in humans(48). Thus, our data are 
consistent with animal and human interventional studies of simvastatin.  
 
This work has limitations. For much of our experimental work, only neutrophil migration was 
reported. However, the process of cytoskeletal rearrangement required to support migration is 
fundamental to neutrophil functions and simvastatin did not impact on phagocytosis or NETosis in 
the clinical trial in healthy elders, suggesting these vital neutrophil functions would not be 
compromised with statin treatment. Studies of neutrophil functions with statin exposure in patients 
with infection were in vitro and need confirmation in clinical trials.  Furthermore, prospective 
studies in at risk populations would be needed to confirm whether reduced neutrophil migratory 
accuracy precedes or is a feature of infection in the elderly. Most studies were conducted using 
one or two chemo-attractants, which does not reflect the inflammatory milieu of biological fluids, 
however migration studies were repeated using neutrophils from donors with CAP migrating 
towards CAP-sputum, yielding consistent findings. Our studies utilised the previously globally 
accepted definition of sepsis(22), and patient groups have been maintained using these definitions to 
allow comparison to the published literature, however, when the newly suggested definitions(49) 
were applied, all patients with sepsis would still be considered as such.   Chemokine receptors 
were not measured on neutrophils during infectious episodes, and although these do not appear 
altered with age in health(3), we cannot exclude changes in expression as contributing to the 
reduction in chemotaxis. Neutrophil chemotaxis values to BIRT-377 were lower than measured 
elsewhere in this body of work, which is likely to reflect the use of ethanol as an initial diluent for 
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this compound and the associated vehicle control, but the use of this inhibitor was still able to 
improve migratory accuracy to CXCL8 in cells from old adults, and thus is in keeping with our 
proposed hypothesis.  
Conclusions 
Neutrophil migratory accuracy is reduced in old patients with respiratory infections, and this 
decline in migratory accuracy is worse with worsening infection severity and does not improve 6 
weeks after the initial event.  Simvastatin can improve migratory accuracy in clinical trials in the 
healthy elderly and (in vitro) in old patients with mild to moderate infections, but not in a severe 
septic event nor at low dose. The mechanism of the migratory defect relates in part to increased 
adhesion molecule expression, which simvastatin normalised in vitro.  
Statins do not appear to improve survival in severe sepsis and acute respiratory distress syndrome.  
However, our studies would support a randomised clinical trial in older patients with pneumonia 
but without severe sepsis (a less severe clinical group than has been studied before) as in vitro 
studies show evidence of benefit.  
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Tables  
Table 1: Demographic data for participants  
 
GROUP 
OH^ YH^ LRTI 
OLD 
LRTI 
YOUNG 
CAP 
OLD 
CAP 
YOUNG 
S-CAP 
OLD 
S-CAP 
YOUNG 
PRIOR 
STATIN 
USE$ 
N 10 10 10 8 10 10 10 10 10 
AGE 72 (64-78) 
27 
(21-32) 
75 
(65-81) 
29 
(21-32) 
73 
(66-86) 
31 
(23-34) 
76 
(65-84) 
29 
(19-34) 
74 
(62-78) 
SEX 
(MALES) 
5  
(50%) 
5  
(50%) 
6  
(60%) 
5  
(63%) 
7  
(70%) 
6  
(60%) 
6  
(60%) 
6  
(60%) 
6  
(60%) 
CAP ON 
XRAY 
0 0 0 0 10 10 10 10 0 
TEMP 37.2 (36.3-37.4) 
37.3 
(36.7-37.4) 
37.3 
(36.5-37.4) 
37.5 
(37.4-37.9) 
37.6 
(36.0-37.6) 
37.7 
(36.3-37.9) 
38.1 
(35.2-38.9) 
38.8 
(37.5-40.2) 
36.9 
(36.6-37.0) 
RR 14 (12-16) 
14 
(12-18) 
16 
(12-20) 
15 
(14-18) 
18 
(12-20) 
19 
(14-20) 
26 
(18-38) 
28 
(16-34) 
16 
(14-18) 
HR 68 (60-88) 
74 
(72-90)* 
92 
(62-102) 
90 
(640100) 
98 
(65-102) 
93 
(72-114) 
116 
(97—127) 
110 
(100-145) 
75 
(69-86) 
WCC N/A N/A 13.8 (10-17) 
14.3 
(9-15) 
17.4 
(11-24) 
16.7 
(12-23) 
19.2 
(15-23) 
19.4 
(16-29) 
N/A 
SOFA N/A N/A 0  (0-1) 
0  
(0-1) 
1  
(0-2) 
1  
(0-2) 
3  
(2-4) 
3  
(2-4) 
N/A 
APACHE 
II 
N/A N/A 3 
(2-5)* 
0 
(0-1) 
6 
(5-8)* 
4 
(2-4) 
24 
(12-28)* 
12 
(5-32) 
N/A 
CRP  2  (0-4) 
4 
(2-5)* 
33 
(12-46)* 
19 
(8-22) 
91 
(52-139)* 
69 
(21-97) 
159 
(84-181)* 
116 
(98-146) 
3  
(1-4) 
 
Legend:  Demographic data, baseline severity scores and clinical data for healthy subjects, patients 
with a LRTI, Pneumonia (CAP) or Sepsis (S-CAP) and patients on statins. Age is presented as 
median and range.  Sex is number of males and percentage. CAP on X-ray is the number of 
participants with new consolidation on chest radiograph. Temp is the temperature on admission in 
O Centigrade (median and range).  RR = Respiratory rate in breaths per minute (median and 
range).  HR = Heart rate in beats per minute (median and range).  WCC = total white count 
(109/L), median and range.  CRP= C reactive protein (median and range) in mg/L.  Sepsis was 
defined as the presence of SIRS, which includes 2 or more of a temperature of < 36OC or > 38OC, 
a heart rate of > 90bpm, a Respiratory rate > 20 breaths per minute and a Leucocytosis > 12 x 10 x 
106/ml. All medical diagnoses confirmed by physician and laboratory cultures where relevant. 
SOFA and Apache II Scores were from day of recruitment. Mann Whitney U tests were used to 
compare Old to Young parameters. ^ These subjects were medication free.  $For patients on 
statins, 3 were taking beta blockers (5-10mg Bisoprolol), 2 were taking amlodipine 5-10mg, 2 
were taking ramipril (10mg) and 5 were taking bendroflumethiazide (2 – 5mg) as regular 
medication.  * = p<0.05, difference from young participants in the same group. 
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Table 2:  The demographic and physiological characteristics of trial participants upon 
recruitment 
 PATIENT CHARACTERISTICS 
AGE, MEAN (RANGE), YEARS 71.9 (60-94) 
GENDER, N (%), MALES 9 (43%) 
SMOKER 
NEVER, N 
EX-, N (PYH) 
CURRENT, N (PYH) 
 
13 
6 (21.5) 
2 (21.5) 
CO-MORBID CONDITIONS 
HYPERTENSION 
 
6 
MEDICATIONS 
ANTI-HYPERTENSIVE DRUGS 
ACEI 
DIURETICS 
CA2+ CHANNEL BLOCKER + DIURETIC 
BETA-BLOCKER  
 
 
1 
1 
3 
1 
OXYGEN SATURATIONS (%) 97 (96-98) 
FEV1*, MEAN ± SD   (% PREDICTED) 2.67±0.7 (115.5±19.1) 
FVC*, MEAN ± SD  (% PREDICTED) 3.57±0.8 (123.3±21.9) 
BMI, MEAN ± SD 26.04±3.7 
BLOOD PRESSURE (MMHG)  142 (132-149) 
CREATININE (ΜMOL/L)  79 (69.5-80.5) 
ALT (ΜMOL/L)  17 (15-22) 
BILIRUBIN (ΜMOL/L)  8 (7-10) 
CK (IU/L)  80 (59.5-134.5) 
TSH (MU/L) 1.9 (1.1-3.7) 
 
Legend: All values represent the median (IQR), unless otherwise stated. PYH: pack year history. 
FEV1: Forced expiratory volume in 1 second. FVC: Forced Vital Capacity. BMI: Body mass 
index. ALT: Alanine Transferase. CK: Creatinine Kinase. ACEi =Angiotensin Converting 
Enzyme inhibitor. Ca2+: Calcium. * FEV1 measured in litres/sec and FVC measured in litres. 
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Table 3:  Results of the randomised cross over double blinded clinical trial of simvastatin in 
healthy older adults. 
     BASELINE              PLACEBO     SIMVASTATIN P VALUE 
  Post Difference Post Difference  
Phagocytosis       
E. coli 936.8 
(492.4-1675) 
1497 
(1171-2059) 
690.0 
(-79.0-1207) 
1548 
(1282-2158) 
580 
(-22.0-1347) 0.404 
S. aureus  1291 
(660.1-2494)) 
1570 
(1128-2214) 
1217 
(-588.7-2048.0) 
1525 
(997.8-1959) 
257 
(-616.7-1951) 0.196 
Netosis        
PMA  47566 
(27859-65272) 
44363 
(31546-56273) 
6964 
(-17992 – 22048  
46974 
(32631-55913) 
5985 
(-24415-30189) 0.729 
FMLP  1570 
(-1029-3416) 
-416 
(-1618-700) 
1099 
(-2818 – 2719) 
3196 
(-2749-6856) 
1355 
(-2133-6518) 0.216 
LPS 1202 
(-1067-2299) 
1451 
(34.1-3496) 
4048 
(2833 – 6279) 
1202 
(-1067-2299) 
7115 
(-839.1-9851) 0.596 
 
Legend.  All data represented as median change and IQR with p-values from a Wilcoxon-signed 
rank test. Values show baseline median and IQR results and the change from baseline neutrophil 
function following treatment with simvastatin and placebo (N=20 in each group). Phagocytosis 
was assessed in Phagocytic index (PI).  NETosis was assessed in Arbitrary Fluorescent Units 
(AFUs). PMA: Phorbol-12-myristate-13-acetate. fMLP: N-formylmethionyl-leucyl-phenylalanine. 
CXCL-8: Interleukin-8 LPS: Lipopolysaccharide 
Table 4.  Neutrophil surface expression of adhesion markers 
 CD11a CD11b CD18 CD11b act 
YH 1105 
(930.5 -1344.0) 
3065.5 
(2709 - 3486) 
43722 
(33220 - 48463) 
1728 
(1473 - 2086) 
OH 2043.6 
(1770 - 2171)1 
4131 
(3644 - 4812)2 
48074 
(41633 - 51738) 
2116 
(1936 - 3149) 
Old CAP 2648 
(2113 - 3126)3 
4839 
(4149 - 6509)4 
Not measured Not measured 
OH Simvastatin 1356 
(1141-1623)5 
3674 
(3407 - 3906) 
Not measured Not measured 
OH VC 1830 
(1643 – 2301.2) 
3659 
(3351 - 4112) 
Not measured Not measured 
 
Legend. All measurements were conducted in cells in whole blood, see methods section. YH = 
young healthy control. OH = old healthy control.  Old CAP = Old patient with community 
acquired pneumonia. OH Simvastatin = whole blood from OH treated with 1µM Simvastatin.  OH 
VC = whole blood from OH treated with vehicle control for simvastatin. Data is expressed as 
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median fluorescence index (IQR) and compared using Mann Whitney U tests.  There were 10 
subjects in each group. OH were compared to YH. 1 = p=0.0007, 2 = p=0.0063.  CAP expression 
was compared to OH. 3 = p = 0.03, 4 = compared to OH, p=0.07. OH Simvastatin was compared to 
OH VC.  5 = p=0.04.  
 
Figure Legends 
Figure 1:  Changes to neutrophil chemotaxis during respiratory infections and recovery 
Figure 1a Neutrophil chemotaxis during infections 
Neutrophils were isolated from healthy subjects (HC) aged >60years (n = 10) or < 35 years (n=10) 
and from age matched patients within 24 hours of being treated for a lower respiratory tract 
infection (LRTI, n=10 aged > 60 and n=8 < 35 years), community acquired pneumonia (CAP, 
n=10 aged > 60 and n=10 aged < 35 years) or pneumonia associated with sepsis (S-CAP, sepsis 
n=10 both groups).  Each data point is a single subject and the median and IQR are shown with 
error bars.  In older subjects, neutrophil migration displayed reduced accuracy towards CXCL8 
(100nM) as the infectious insult severity progressed (Kruskall Wallis, p=0.0001). A post-hoc 
Dunn’s Multiple Comparison test confirmed there was no significant difference between older 
healthy controls and patients with a LRTI (adjusted p=0.32) but there was a statistical difference 
between healthy controls and older patients with CAP (p=0.0021) and S-CAP (p<0.0001) and 
LRTI and S-CAP (p=0.011) but not CAP and S-CAP (adjusted p value = 0.845).  In young adults, 
no such deterioration was (across infectious insults, Kruskall Wallis, p=ns) but neutrophil 
migratory accuracy was reduced in sepsis compared to health, Mann-Whitney test, p=0.01) 
 
Figure 1b:  Changes to neutrophil chemotaxis during pneumonia and 6 weeks after 
recovery. 
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Neutrophils were isolated from young (age < 35years) and old (age >60 years) patients admitted 
with a community acquired pneumonia (CAP) (n=10 for each group) and 6 weeks later, following 
a clinical recovery as demonstrated by no symptoms compatible with infection, no physiological, 
biochemical or haematological evidence of infection and a recovered chest radiograph (CAP-R). 
Each data point is a single subject with CAP and recovery data for the same patient linked by a 
broken line. Cells migrated towards CXCL8 (100nM).  CAP and recovery results (CAP-R) were 
compared with age-matched either old or young healthy controls (HC) who self-reported having 
never had a pneumonia (n=10 for each group), Mann Whitney.   
 
Figure 2:  Changes to neutrophil chemotaxis following in vitro exposure to Simvastatin; Dose 
response.   
Neutrophils were isolated from healthy subjects aged >60years (n=10) and incubated for 40 
minutes with Simvastatin (Sim - at the concentrations given) or vehicle control (VC).  Each data 
point is a single subject and the median and IQR are shown with error bars. The accuracy of 
neutrophil migration towards CXCL8 (100 nM) was assessed and found to be improved following 
incubation from 1nM – 1uM statin compared with vehicle control across the whole group, 
(Kruskall Wallis, p = 0.0022). A post-hoc Dunn’s Multiple Comparison test confirmed there were 
significant differences between neutrophil migratory accuracy when incubated with 100nM 
(adjusted p value 0.023) and 1uM (adjusted p value 0.0018) Simvastatin, compared with the 
vehicle control. 
 
Figure 3:  Changes to neutrophil chemotaxis in patients during respiratory infections; the 
effects of in vitro simvastatin 
Peripheral neutrophils were isolated from old (age >60 years) (Figure 3A) or young (age <35) 
patients (Figure 3B) with a lower respiratory tract infection (LRTI old, n =10; young, n=8), 
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pneumonia (CAP, n =10 for both) and pneumonia-associated sepsis (S-CAP, n =10 for both) and 
incubated with 1µM simvastatin or vehicle control (VC) for 40 minutes. For both figures, each 
data point is a single subject and the median and IQR are shown with error bars. Simvastatin 
improved neutrophil migration from old patients with LRTI (p=0.008) and also old patients with 
pneumonia (p=0.01) but not patients with sepsis, whose neutrophils remained poorly chemotactic 
(Wilcoxon signed-rank test for all). Simvastatin did not impact on neutrophil migration from 
young adults in any group.  
 
Figure 4. Modified Consort Diagram.  
Legend. Modified consort diagram of the screening and recruitment of subjects in the randomised 
controlled double blind cross over study of Simvastatin 80mg orally daily or placebo, showing the 
number of subjects who had complete sets of functional neutrophil experiments carried out. 
 
Figure 5.  Changes in neutrophil migratory accuracy after a two-week course of high dose 
simvastatin and placebo. 
Healthy older adults had neutrophil migratory accuracy measured at baseline towards CXCL8 and 
fMLP.  They were then randomised in a double blinded cross-over trial to receive 80mg 
Simvastatin or placebo for 2 weeks when neutrophil migration towards the chemo-attractants was 
reassessed.  There was a two week wash out period and then the alternative blinded therapy was 
taken, with neutrophil functions re-assessed at the end of this two week course.  Figure A 
compares neutrophil migration at baseline to post Simvastatin treatment.  Figure B compares 
neutrophil migration at baseline to post placebo treatment.  Each data point is one subject, with pre 
and post treatment or placebo neutrophil migration indices linked via a line.  The median 
difference between baseline and treatment or placebo neutrophil migration was assessed using 
Wilcoxon signed rank tests and holm-bonferroni correction applied for multiple comparisons. * = 
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statistically significant after multiple comparison correction.  $ = not statistically significant after 
multiple comparison correction. 
 
Figure 6:  Changes to neutrophil chemotaxis following treatment with a CD11a inhibitor 
Legend. Peripheral neutrophils were isolated from old (age >60 years) and young (<35 years) 
healthy adults patients and incubated with 26nM BIRT-377 or vehicle control (VC) for 40 
minutes. Each data point is a single subject and the median and IQR are shown with error bars. 
BIRT-377 improved neutrophil migratory accuracy from old participants, p=0.03) but reduced 
chemotaxis (p=0.006) of neutrophils from young participants, (n=10 for each group).  Data is 
shown as vehicle control treated neutrophils migrating to CXCL8 (VC) or BIRT-377 treated 
neutrophils migrating to CXCL8 (BIRT-377).  Data comparisons are analysed using Wilcoxon 
ranked sign tests.  
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